Skip to main content
Premium Trial:

Request an Annual Quote

Japan Regulators Approve AmoyDx's Lung Cancer CDx

NEW YORK (GenomeWeb) – Chinese firm Amoy Diagnostics said today that Japan regulators have approved its ROS1 fusion PCR assay as a companion diagnostic for Pfizer's ROS1 inhibitor Xalkori (crizotinib).

Japan's Pharmaceuticals and Medical Devices Agency approved the OncoGuide AmoyDx ROS1 fusion kit for identifying advanced non-small cell lung cancer patients with ROS1 gene fusions. Based on RT-PCR technology, the kit identifies 14 ROS1 gene fusions by analyzing tumor messenger RNA from human tumor tissue or body fluids. Results can be achieved in 2.5 hours.

The kit received CE mark in 2013 and was approved by China's Food and Drug Administration in 2014. AmoyDx CEO Li-Mou Zheng said in a statement that the firm expects to soon receive regulatory approval for the kit in South Korea and Taiwan.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.